Quan Capital
VC Fund
Shanghai, China
Quan Capital is a VC fund in Shanghai focused on Biotechnology and Health Care. Quan Capital discover, incubate and grow next-generation life sciences companies. Their unique investment philosophy enables us to explore disruptive solutions to critical healthcare problems impacting the lives of millions. Their portfolio companies are pioneers in breakthrough therapies and cutting-edge technologies that will generate significantvalue to patients. In addition, they are investing in leading players that fulfill the rapid growing needs in a nascent innovation driven eco-system in China.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 26%
- Fund size:
- $350M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Quan Capital invests in
Stages Quan Capital invests in
Countries Quan Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 16 (38%)
- Health Care 13 (31%)
- Pharmaceutical 11 (26%)
- Biopharma 9 (21%)
- Medical 7 (17%)
Stage
- Series B 13 (31%)
- Series A 11 (26%)
- Funding Round 3 (7%)
- Series C 2 (5%)
- Seed 1 (2%)
Country
- United States 12 (29%)
- China 9 (21%)
- Hong Kong 1 (2%)
- Switzerland 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Marietta Wu
Managing Director
|
Managing Director | Total investments: 9 | Find email | |
Peter Wirth
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Samantha DU
Founder & Managing Director
|
Founder & Managing Director | Total investments: 0 | Find email | |
Stella Xu
Managing Director
|
Managing Director | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | |
Pinnacle Medicines
|
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. | $89M / Series B / Mar 26, 2026 | |
Avenzo Therapeutics
|
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $60M / Series B / Sep 04, 2025 | |
|
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $200M / Series A / Jan 10, 2025 | |
|
Avenzo Therapeutics
|
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $50M / Series A / Nov 18, 2024 | |
Zenas BioPharma
|
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. | $200M / Series C / May 07, 2024 | |
|
Avenzo Therapeutics
|
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $150M / Series A / Mar 26, 2024 | |
Crescendo Biologics
|
Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $32M / Jul 24, 2023 | |
Adcentrx Therapeutics
|
Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies forimproving patient treatment options. | $51M / Series A / Apr 24, 2023 | |
Alebund Pharmaceuticals
|
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $29.1M / Series C / Apr 12, 2023 | |
| See all 42 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Quan Capital invest in?
Quan Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 42 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Quan Capital?
Public channels for Quan Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Quan Capital?
The team at Quan Capital includes Marietta Wu (Managing Director), Peter Wirth (Venture Partner) and Samantha DU (Founder & Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
